Tag - FBRX

Developments

Forte Biosciences doses first patient in Phase 2 atopic dermatitis trial

Forte Biosciences (NASDAQ:FBRX) dosed the first patient in its Phase 2 trial evaluating FB-401 for the treatment of atopic dermatitis. FB-401 is a topical mixture comprised primarily of three strains of the commensal...

September 29, 2020

Markets

Brookline starts Forte Biosciences at buy; PT $90

Brookline Capital Markets launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $90 price target. The stock closed at $26.69 on Aug. 27. Forte Biosciences is developing FB-401, a topical live...

August 28, 2020

Markets

Ladenburg starts Forte Biosciences at buy; PT $60

Ladenburg Thalmann launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $60 price target. The stock closed at $14.31 on June 19. Forte is focused on the treatment of inflammatory skin diseases...

June 22, 2020

Tag - FBRX

Forte Biosciences doses first patient in Phase 2 atopic dermatitis trial

Brookline starts Forte Biosciences at buy; PT $90

Ladenburg starts Forte Biosciences at buy; PT $60

General

More